Form 4: Teladoc CEO Divita Sells Shares for Tax Obligations

Teladoc Health CEO Charles Divita III reported the conversion of restricted and performance stock units and the sale of shares to cover tax withholding obligations.

Summary

• Teladoc Health CEO Charles Divita III reported multiple transactions involving company stock, including the acquisition of shares from vested equity awards and the sale of shares for tax purposes.
• On February 27, 2022, 169,107 shares of common stock were acquired through the conversion of restricted stock units (RSUs).
• On February 27, 2026, an additional 7,864 shares of common stock were acquired through the conversion of performance stock units (PSUs).
• On March 2, 2026, 50,145 shares of common stock were sold at a price of $5.117 per share.
• The sale of shares was explicitly conducted to cover tax withholding obligations related to the vesting of the reporting person's performance stock unit and restricted stock unit awards.
• Following these reported transactions, Charles Divita III directly beneficially owns 327,862 shares of Teladoc Health common stock.
• The filing also corrected a typo from a previous Form 4, adjusting a restricted stock unit grant on March 1, 2025, from 507,332 units to 507,322 units.
• New grants of 23,591 performance stock units and 692,041 restricted stock units were reported, with specific vesting schedules outlined for each.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While there's a sale of shares, it's explicitly for tax purposes related to vested equity, which is a routine event and indicates the executive is receiving compensation. The new grants of RSUs and PSUs are positive for executive alignment.

Positives

• Vesting of restricted stock units (RSUs) and performance stock units (PSUs) indicates the achievement of performance metrics or time-based vesting conditions, reflecting executive compensation.
• New grants of 23,591 performance stock units and 692,041 restricted stock units demonstrate ongoing equity compensation for the CEO, aligning executive interests with shareholder value.

Negatives

• The sale of 50,145 shares, even for tax purposes, results in a reduction of the CEO's direct beneficial ownership in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions like those reported in a Form 4 are common for executives receiving equity compensation. The sale to cover tax obligations is a standard practice and does not necessarily reflect a change in management's outlook on the company's future.

Comparison to Industry Standards

• Routine tax-related stock sales by executives are a common practice across industries for managing equity compensation. For example, similar transactions are frequently observed in tech companies like Microsoft (MSFT) or Apple (AAPL) where executives often sell a portion of vested shares to cover statutory tax withholdings, rather than indicating a lack of confidence in the company's prospects.
• The vesting schedules and grant sizes are typical for a CEO of a company of Teladoc's size, aligning with general market practices for executive compensation in the healthcare technology sector.

Stakeholder Impact

• Shareholders: The sale for tax purposes is a minor reduction in insider ownership but is a common practice. The vesting and new grants align executive interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of remaining restricted stock units and performance stock units in eight substantially equal quarterly installments after March 1, 2026.

Key Dates

Recommendation

The filing details routine insider transactions related to equity compensation and tax obligations. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and do not signal a significant positive or negative shift in the company's outlook.

Keywords

Teladoc Health, TDOC, Form 4, Insider Trading, Charles Divita III, CEO, Restricted Stock Units, Performance Stock Units, Stock Sale, Equity Compensation, SEC Filing